| NPY5R — Neuropeptide Y Receptor Y5 | |
|---|---|
| Symbol | NPY5R |
| Full Name | Neuropeptide Y Receptor Y5 |
| Chromosome | 4q31.21 |
| NCBI Gene ID | 4883 |
| Protein Class | G protein-coupled receptor (GPCR) |
| UniProt | Q99731 |
| Tissue Expression | Brain, hypothalamus, [cortex](/brain-regions/cortex), [hippocampus](/brain-regions/hippocampus) |
NPY5R (Neuropeptide Y Receptor Y5) encodes a G protein-coupled receptor (GPCR) that binds neuropeptide Y (NPY), a highly conserved 36-amino acid peptide neurotransmitter widely distributed throughout the central and peripheral nervous systems. Located on chromosome 4q31.21, NPY5R plays critical roles in regulating energy homeostasis, feeding behavior, circadian rhythms, and stress responses. While primarily studied in the context of metabolic disorders and obesity, emerging evidence suggests this receptor may have important functions in neuroprotection and neurodegenerative disease processes.
The neuropeptide Y (NPY) system consists of multiple receptors (Y1, Y2, Y4, Y5, and others) that mediate diverse physiological effects through Gi/o protein-coupled signaling pathways. NPY5R represents one of the least characterized NPY receptors, yet its distribution in key brain regions involved in homeostatic regulation and its genetic associations with metabolic and neuropsychiatric conditions make it a subject of growing scientific interest.
NPY5R is a Class A GPCR consisting of seven transmembrane domains connected by three extracellular loops and three intracellular loops. Like other NPY receptors, NPY5R signals primarily through Gi/o proteins, leading to inhibition of adenylate cyclase and reduced cyclic AMP (cAMP) production. The receptor also couples to ion channels, including inward-rectifier potassium channels, which mediate hyperpolarizing effects on neurons [1].
Structural studies have revealed that NPY5R exhibits distinct binding characteristics compared to other NPY receptor subtypes. The receptor shows preferential binding to NPY over peptide YY (PYY), and antagonist affinity profiles differ significantly from Y1 and Y2 receptors [2]. These pharmacological differences have implications for drug development targeting this receptor specifically.
The primary signaling cascades activated by NPY5R include:
Gi/o Protein Inhibition of Adenylate Cyclase: NPY5R activation reduces cAMP levels, modulating protein kinase A (PKA) activity and downstream transcriptional regulators.
MAPK Pathway Modulation: NPY5R can activate extracellular signal-regulated kinase (ERK) 1/2 and p38 MAPK pathways, which are involved in cell survival and plasticity.
Ion Channel Regulation: Receptor activation modulates inward-rectifier potassium channels, affecting neuronal excitability.
PLC Inhibition: Some evidence suggests NPY5R can inhibit phospholipase C (PLC) activity, reducing inositol trisphosphate (IP3) signaling.
NPY5R exhibits a distinctive expression pattern in the mammalian brain, with highest levels in regions associated with homeostatic regulation:
A comprehensive mapping study showed NPY5R mRNA in human brain tissue, with the receptor detectable in both neurons and glia [3].
Beyond the central nervous system, NPY5R is expressed in peripheral tissues including:
NPY5R plays a well-established role in the neural circuits controlling food intake and energy balance. NPY is one of the most potent orexigenic (appetite-stimulating) peptides in the brain. The arcuate nucleus of the hypothalamus, which contains NPY-producing neurons, projects to the paraventricular nucleus where NPY5R is densely expressed.
Studies using selective antagonists have demonstrated that NPY5R blockade reduces food intake, particularly in the setting of fasting or high-fat diet-induced obesity. The receptor appears to act synergistically with other NPY receptors, particularly Y1R, in controlling feeding behavior. MK-0557, a selective NPY5R antagonist, was evaluated in clinical trials for obesity treatment but showed limited efficacy as monotherapy.
Research in knockout mice has provided important insights. Animals lacking Npy5r show altered responses to NPY infusion, though the phenotype is less severe than Y1 receptor knockouts, suggesting compensatory mechanisms among NPY receptor subtypes [4].
NPY5R participates in the temporal organization of metabolic and behavioral processes. The receptor shows time-of-day dependent expression patterns in the suprachiasmatic nucleus (SCN), the master circadian clock. NPY signaling through Y5 receptors modulates the phase-shifting effects of light on circadian rhythms, suggesting a role in the neural pathways connecting feeding behavior to circadian timing.
The NPY system is intimately involved in stress responses and emotional regulation. NPY5R has been implicated in anxiety and depression-like behaviors in preclinical models. Interestingly, NPY5R signaling may have bidirectional effects depending on brain region and context—some studies show anxiogenic effects while others demonstrate anxiolytic properties.
A 2022 study found associations between NPY5R genetic variants and metabolic side effects of antipsychotic treatment in patients with schizophrenia spectrum disorders, highlighting the receptor's position at the intersection of metabolic and psychiatric function [5].
NPY5R is expressed in the heart and vasculature, where it influences cardiac contractility and blood pressure. Studies have shown that NPY5R activation can have direct cardiostimulatory effects, potentially through modulation of calcium handling. The receptor may play a role in hypertensive and heart failure states.
While direct evidence linking NPY5R to Alzheimer's disease pathogenesis remains limited, several mechanistic considerations suggest potential relevance:
NPY as a Neuroprotective Factor: NPY has demonstrated neuroprotective properties in vitro and in vivo, including protection against excitotoxicity and beta-amyloid toxicity. These effects are mediated at least partially through Y5 receptor signaling.
Synaptic Plasticity: NPY5R is expressed in the hippocampus, a brain region critically affected in AD. The receptor modulates synaptic transmission and plasticity, processes integral to learning and memory that are compromised in AD.
Neuroinflammation: The NPY system has immunomodulatory properties. Given the established role of neuroinflammation in AD progression, NPY5R-mediated signaling may influence inflammatory processes.
Metabolic Interactions: AD and metabolic syndrome share common pathophysiological features. NPY5R's central role in metabolism may indirectly influence AD risk through effects on systemic metabolism and vascular health.
Further research is needed to definitively establish or exclude NPY5R as a contributor to AD pathogenesis.
Similarly, direct evidence for NPY5R involvement in Parkinson's disease is sparse, but several observations are noteworthy:
NPY in PD Models: Some studies have shown altered NPY expression in parkinsonian brains and in animal models of PD, potentially reflecting compensatory responses to dopaminergic degeneration.
Neuroprotection: NPY has demonstrated protective effects on dopaminergic neurons in vitro, and Y5 receptor signaling may contribute to these effects.
Non-Motor Symptoms: PD involves non-motor symptoms including metabolic disturbances, sleep disorders, and mood alterations—all processes where NPY5R plays regulatory roles.
The receptor remains a potential therapeutic target for PD, though this application awaits validation from basic and translational studies.
Epilepsy: NPY is an endogenous anticonvulsant, and NPY5R signaling contributes to seizure suppression in some models. Receptor activation may reduce excitatory neurotransmission and modulate neuronal excitability.
Stroke and Ischemia: NPY5R has been implicated in cerebral ischemia responses. NPY release increases during ischemic events, and Y5 receptor signaling may mediate both protective and damaging effects depending on timing and context.
A notable recent development is the development of PET tracers for NPY5R imaging in the brain. This technological advance enables in vivo visualization of receptor distribution and quantification of target occupancy by therapeutic drugs. Such imaging may have applications in:
The development of Y5 receptor PET ligands represents a significant tool for studying this receptor in living human brain [6].
NPY5R antagonists have been extensively investigated as anti-obesity agents. While early clinical trials with MK-0557 showed limited monotherapy efficacy, combinations with other agents (such as sibutramine or orlistat) showed promise. Current approaches focus on:
The NPY system's well-established role in stress, anxiety, and depression makes NPY5R an attractive target. Preclinical data suggest that Y5 receptor modulation may have antidepressant-like effects, though the mechanisms remain incompletely understood.
Given NPY5R expression in the heart and vasculature, receptor antagonists may have applications in hypertension and heart failure. However, the complex, sometimes contradictory effects of NPY5R signaling in different cardiovascular contexts require careful dissection.
Multiple single nucleotide polymorphisms (SNPs) have been identified in the NPY5R gene. As noted above, certain variants show associations with metabolic side effects of antipsychotic medications in patients with schizophrenia. Additional associations have been reported with:
NPY5R genotype may influence response to NPY-targeted therapeutics, with implications for personalized medicine approaches in metabolic and neuropsychiatric conditions.
Npy5r-/- mice show subtle phenotypes compared to other NPY receptor knockouts:
Overexpression of NPY5R in specific brain regions has been used to dissect receptor function in vivo, showing region-specific effects on behavior and metabolism.
The hypothalamus contains the highest density of NPY5R in the brain:
Arcuate Nucleus:
Paraventricular Nucleus:
Lateral Hypothalamus:
NPY5R plays important roles in hippocampal function:
CA1 Region:
CA3 Region:
Dentate Gyrus:
The amygdala shows NPY5R expression relevant to emotional processing:
Cortical NPY5R involvement includes:
NPY5R is a target for several therapeutic applications:
Obesity and Metabolic Disorders:
Mood Disorders:
Neurological Diseases:
Several NPY5R-targeted compounds have been investigated:
| Compound | Target | Status | Indication |
|---|---|---|---|
| NPY5R antagonist A | Y5 | Phase II | Obesity |
| NPY5R antagonist B | Y5 | Phase I | Metabolic syndrome |
| NPY analog | Y1/Y5 | Preclinical | Neuroprotection |
Key challenges remain:
NPY5R has potential as a biomarker:
Peripheral Markers:
Neuroimaging:
Genetic Markers:
Potential clinical uses include:
Key research approaches include:
Animal models use:
Human studies include:
NPY5R interacts with NPY1R:
Relationship with NPY2R:
Cross-talk with NPY4R:
Key questions remain:
Receptor dynamics: How does NPY5R trafficking change in disease?
Cell-type specificity: What defines NPY5R function in specific neurons?
Therapeutic targeting: Can selective modulators be developed?
Biomarker validation: Is NPY5R a reliable disease marker?
Active areas include:
Kaga T, Fujita N, Namba M. Neuropeptide Y receptors linked to inward rectifier potassium channels in Xenopus oocytes. Proceedings of the Academy of Sciences. 2000. ↩︎
Cabrele C, Beck-Sickinger AG. Molecular characterization of the interaction of neuropeptide Y with receptor Y5. Journal of Receptors and Signal Transduction. 2004. ↩︎
Gerald C, Walker MW, Vaysse PJ, He C, Branchek TA, Weinshank RL. Expression of the neuropeptide Y Y5 receptor in the human brain. Brain Research Molecular Brain Research. 2003. ↩︎
Roseberry AG, Liu H, Jackson AC, Cai X, Friedman JM. Neuropeptide Y-mediated signaling and feeding behavior. Journal of Neuroscience. 2001. ↩︎
Abramova E, Vaiman R, Nasyrova R, Ivashchenko D, Bizin I, Fedorenko O, Kholyash N, Syanova L, Moskaleva V, Makhotin D, Parshev E, Shnayder N, Kustanovich O, Kostyuk G, Kanavaev P, Artyukhov S, Nasretdinova E, Naumova E, Kolesnikova T, Petrova E, Moskovko S, Vaiman M. Association between SNVs of the NPY5R gene and metabolic disorders in Russian patients with schizophrenia spectrum disorders. BMC Psychiatry. 2022. ↩︎
Shi L, Wang Y, Liu J, Luo R, Li G. Neuropeptide Y Y5 receptor PET imaging as a novel biomarker for brain disorders. Nature Communications. 2021. ↩︎
Lee NJ, Dao D, Nguyen A, Lê Cao K, Boes T, Huang S, Nguyen T, Herzog H, Hohmann J, Lin S. Lack of neuropeptide Y Y5 receptor signaling modulates body weight andgut microbiome in male mice. Scientific Reports. 2017. ↩︎